Last reviewed 2026-06-03 · How we verify

Open single period A140

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase 3 active Small molecule Under review

Open single period A140 is a CD47 inhibitor Small molecule drug developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. It is currently in Phase 3 development for Relapsed or refractory acute myeloid leukemia, Relapsed or refractory non-Hodgkin lymphoma. Also known as: KL-140.

A140 is a monoclonal antibody targeting CD47.

A140 is being studied as a potential treatment for metastatic colorectal cancer in a Phase III clinical trial. In this trial, the efficacy and safety of A140, combined with mFOLFOX6, are being compared to Erbitux in patients with Ras wild-type metastatic colorectal cancer.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Open single period A140
Also known as	KL-140
Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Drug class	CD47 inhibitor
Target	CD47
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

CD47 is a protein that inhibits phagocytosis, and by blocking it, A140 aims to enhance the immune system's ability to recognize and destroy cancer cells. This mechanism is thought to be particularly effective in treating hematological malignancies.

Approved indications

Relapsed or refractory acute myeloid leukemia
Relapsed or refractory non-Hodgkin lymphoma

Common side effects

Neutropenia
Thrombocytopenia
Anemia

Key clinical trials

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Open single period A140 CI brief — competitive landscape report
Open single period A140 updates RSS · CI watch RSS
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about Open single period A140

What is Open single period A140?

Open single period A140 is a CD47 inhibitor drug developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., indicated for Relapsed or refractory acute myeloid leukemia, Relapsed or refractory non-Hodgkin lymphoma.

How does Open single period A140 work?

A140 is a monoclonal antibody targeting CD47.

What is Open single period A140 used for?

Open single period A140 is indicated for Relapsed or refractory acute myeloid leukemia, Relapsed or refractory non-Hodgkin lymphoma.

Who makes Open single period A140?

Open single period A140 is developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (see full Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. pipeline at /company/sichuan-kelun-biotech-biopharmaceutical-co-ltd).

Is Open single period A140 also known as anything else?

Open single period A140 is also known as KL-140.

What drug class is Open single period A140 in?

Open single period A140 belongs to the CD47 inhibitor class. See all CD47 inhibitor drugs at /class/cd47-inhibitor.

What development phase is Open single period A140 in?

Open single period A140 is in Phase 3.

What are the side effects of Open single period A140?

Common side effects of Open single period A140 include Neutropenia, Thrombocytopenia, Anemia.

What does Open single period A140 target?

Open single period A140 targets CD47 and is a CD47 inhibitor.

Drug class: All CD47 inhibitor drugs
Target: All drugs targeting CD47
Manufacturer: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Relapsed or refractory acute myeloid leukemia
Indication: Drugs for Relapsed or refractory non-Hodgkin lymphoma
Also known as: KL-140

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing